Enclomiphene

Enclomiphene is the active trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) that blocks estrogen negative feedback at the hypothalamus and pituitary, stimulating endogenous LH, FSH, and testosterone production. It is widely compounded as a TRT alternative for men seeking testosterone optimization while preserving fertility.

Category
Hormonal Support
Demand
High
Route
Oral capsule
FDA status
Not FDA-approved as standalone compound; available through compounding. Racemic clomiphene (Clomid) is FDA-approved for female ovulation induction
Also known as
Enclomiphene Citratetrans-Clomifene

How Enclomiphene Works

Enclomiphene competitively binds estrogen receptors (ER-alpha) at the hypothalamus and anterior pituitary, blocking the negative feedback of circulating estradiol [3]. This disinhibition increases GnRH pulse frequency, driving increased LH and FSH secretion [1]. The resulting gonadotropin elevation stimulates Leydig cell testosterone production and Sertoli cell spermatogenesis simultaneously, preserving fertility while raising serum testosterone [2].

Clinical Evidence

Phase III clinical trials by Repros Therapeutics (Androxal program) demonstrated that enclomiphene 12.5-25mg daily significantly increased total testosterone, LH, and FSH in men with secondary hypogonadism while maintaining sperm counts [1]. The ZA-304 and ZA-305 trials showed non-inferiority to topical testosterone for testosterone elevation with superior preservation of spermatogenesis [4]. FDA approval was not obtained due to manufacturing issues, not efficacy concerns [1].

Clinical Uses

  • Endogenous testosterone optimization without exogenous hormone use
  • Fertility preservation as an alternative to TRT
  • Secondary hypogonadism treatment (hypothalamic-pituitary origin)
  • Post-TRT recovery and HPTA axis restoration
  • Testosterone support for men not ready to commit to TRT

Patient Selection and Screening

Optimal for men with secondary hypogonadism (low T with low or inappropriately normal LH/FSH), particularly those desiring fertility preservation [2]. Best suited for total testosterone in the 200-400 ng/dL range seeking mild to moderate improvement [3]. Not appropriate for primary hypogonadism (elevated gonadotropins), severe symptomatic deficiency requiring rapid correction, or men who have failed prior SERM therapy [4].

Dosing and Administration

Initiate at 12.5mg daily for 4-6 weeks and recheck total testosterone, free testosterone, LH, FSH, and estradiol [3]. If testosterone response is insufficient (target varies by patient goals), increase to 25mg daily [1]. Some clinicians use every-other-day dosing for maintenance [4]. Lipid panel and visual symptom screening should be performed at baseline and periodically. Discontinue immediately if visual disturbances occur [2].

Route
Oral capsule
Protocol notes
Oral capsule, typically 12.5-25mg daily or every other day. Labs (total testosterone, free testosterone, LH, FSH, estradiol) checked at 4-6 weeks and dose adjusted based on response. Can be used continuously or cyclically.

Safety and Monitoring

Potential side effects

  • Visual disturbances (blurred vision, floaters, photophobia); rare but requires immediate discontinuation
  • Mood changes and irritability (less common than with racemic clomiphene)
  • Hot flashes and vasomotor symptoms (related to estrogen receptor blockade)
  • Headache and nausea (typically mild and transient)
  • Potential impact on lipid profiles (HDL reduction) with chronic use

Clinical considerations

  • Not FDA-approved as standalone (compounded); distinguish from racemic clomiphene (Clomid)
  • Vision changes (blurred vision, floaters) reported rarely; counsel patients to report immediately
  • Monitor estradiol levels (SERM action can alter E2 feedback dynamics)
  • Lipid panel monitoring recommended (SERMs can affect lipid metabolism)
  • Not appropriate for primary hypogonadism (testicular failure); requires functional testes and pituitary

Practice Economics

Enclomiphene is one of the highest-growth compounds in men's health, appealing to patients who want testosterone optimization without injections or fertility compromise [2]. Its oral route and favorable side-effect profile versus racemic clomiphene drive strong patient acceptance and retention [4]. It serves as an effective entry point for new patients, with potential conversion to broader protocols over time. Monthly prescription refills create reliable recurring revenue.

FDA Category Status

Not FDA-approved as standalone compound; available through compounding. Racemic clomiphene (Clomid) is FDA-approved for female ovulation induction

FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify current status before prescribing.

Frequently Asked Questions

What is the advantage of enclomiphene over racemic clomiphene (Clomid)?

Racemic clomiphene contains both trans (enclomiphene) and cis (zuclomiphene) isomers. Zuclomiphene is an estrogen receptor agonist with a long half-life (weeks) that can accumulate and cause estrogenic side effects (mood changes, visual disturbances). Pure enclomiphene provides the anti-estrogenic testosterone-boosting effect without zuclomiphene accumulation, resulting in fewer side effects and a cleaner pharmacologic profile.

How does enclomiphene compare to TRT for testosterone optimization?

Enclomiphene stimulates endogenous testosterone production (preserving fertility and testicular function), while TRT provides exogenous testosterone (suppressing LH/FSH and spermatogenesis). Enclomiphene typically achieves testosterone levels of 500-800 ng/dL, which may be sufficient for many patients. TRT can achieve higher levels. Enclomiphene is preferred when fertility preservation is important or patients prefer to avoid injections.

Which patients are ideal candidates for enclomiphene?

Ideal candidates have secondary hypogonadism (low testosterone with inappropriately normal/low LH), desire fertility preservation, prefer oral medication over injections, are younger men not ready for lifelong TRT, or have mild-to-moderate testosterone deficiency. Poor candidates include those with primary hypogonadism (elevated LH), severe deficiency requiring rapid correction, or those who have failed SERM therapy previously.

References

  1. Repros Therapeutics - Androxal (enclomiphene) Phase III trial results (ZA-304)
  2. Kim et al. - Enclomiphene citrate raises testosterone while preserving sperm counts (2016)
  3. Wiehle et al. - Enclomiphene citrate for secondary hypogonadism: Phase II data (2014)
  4. Kaminetsky et al. - Oral enclomiphene vs topical testosterone in hypogonadal men (2013)

Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable regulations. Always verify FDA category status and compounding eligibility before prescribing.

Launch a Peptide Program With Karpa

Karpa handles intake, licensed prescribing, and direct-to-patient pharmacy fulfillment across all 50 states. No medical license required.

Explore peptide programs